A reasonable risk. I'm going to wait a little while and see if there is any direction coming from the FDA. Since the p1 study was stopped due to problems among the healthy volunteers, I would like to know the direction we are going here...of course, as soon as that is announced it will be reflected in the sp, so I could miss the turn.
Hmmmmm....maybe I'll just pick a target re-entry price.
Market Data 
Markets 
AI
